Combination chemoimmunotherapy for extensive non-oat cell lung cancer

B. F. Issell, M. Valdivieso, E. M. Hersh, Stephen P Richman, J. U. Gutterman, G. P. Bodey

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In a prospective randomized trial, sc Corynebacterium parvum (C. parvum) immunotherapy did not significantly affect the response and survival of 49 non-oat cell lung cancer patients receiving isophosphamide and adriamycin chemotherapy. Remissions (tumor regression > 50%) were seen in five of 23 patients receiving an intensive C. parvum schedule and in three of 26 patients receiving a nonintensive C. parvum schedule (22% versus 12%). Median survival was 20 weeks for patients given intensive C. parvum and 23 weeks for patients given nonintensive C. parvum. This study did demonstrate the importance of pretherapy immunocompetence, performance status, and weight loss as predictors for survival. Weight loss was the most significant prognostic factor. Performance status was closely associated with weight loss but skin reactivity to dermatophytin predicted independently and was the second most important prognostic characteristic.

Original languageEnglish
Pages (from-to)1059-1063
Number of pages5
JournalCancer Treatment Reports
Volume62
Issue number7
StatePublished - Dec 1 1978
Externally publishedYes

Fingerprint

Propionibacterium acnes
Lung Neoplasms
Weight Loss
Survival
Appointments and Schedules
Immunocompetence
Ifosfamide
Immunotherapy
Doxorubicin
Drug Therapy
Skin
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Issell, B. F., Valdivieso, M., Hersh, E. M., Richman, S. P., Gutterman, J. U., & Bodey, G. P. (1978). Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treatment Reports, 62(7), 1059-1063.

Combination chemoimmunotherapy for extensive non-oat cell lung cancer. / Issell, B. F.; Valdivieso, M.; Hersh, E. M.; Richman, Stephen P; Gutterman, J. U.; Bodey, G. P.

In: Cancer Treatment Reports, Vol. 62, No. 7, 01.12.1978, p. 1059-1063.

Research output: Contribution to journalArticle

Issell, BF, Valdivieso, M, Hersh, EM, Richman, SP, Gutterman, JU & Bodey, GP 1978, 'Combination chemoimmunotherapy for extensive non-oat cell lung cancer', Cancer Treatment Reports, vol. 62, no. 7, pp. 1059-1063.
Issell BF, Valdivieso M, Hersh EM, Richman SP, Gutterman JU, Bodey GP. Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treatment Reports. 1978 Dec 1;62(7):1059-1063.
Issell, B. F. ; Valdivieso, M. ; Hersh, E. M. ; Richman, Stephen P ; Gutterman, J. U. ; Bodey, G. P. / Combination chemoimmunotherapy for extensive non-oat cell lung cancer. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 7. pp. 1059-1063.
@article{3531f797705d40f194e0ec7a20a78c7d,
title = "Combination chemoimmunotherapy for extensive non-oat cell lung cancer",
abstract = "In a prospective randomized trial, sc Corynebacterium parvum (C. parvum) immunotherapy did not significantly affect the response and survival of 49 non-oat cell lung cancer patients receiving isophosphamide and adriamycin chemotherapy. Remissions (tumor regression > 50{\%}) were seen in five of 23 patients receiving an intensive C. parvum schedule and in three of 26 patients receiving a nonintensive C. parvum schedule (22{\%} versus 12{\%}). Median survival was 20 weeks for patients given intensive C. parvum and 23 weeks for patients given nonintensive C. parvum. This study did demonstrate the importance of pretherapy immunocompetence, performance status, and weight loss as predictors for survival. Weight loss was the most significant prognostic factor. Performance status was closely associated with weight loss but skin reactivity to dermatophytin predicted independently and was the second most important prognostic characteristic.",
author = "Issell, {B. F.} and M. Valdivieso and Hersh, {E. M.} and Richman, {Stephen P} and Gutterman, {J. U.} and Bodey, {G. P.}",
year = "1978",
month = "12",
day = "1",
language = "English",
volume = "62",
pages = "1059--1063",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Combination chemoimmunotherapy for extensive non-oat cell lung cancer

AU - Issell, B. F.

AU - Valdivieso, M.

AU - Hersh, E. M.

AU - Richman, Stephen P

AU - Gutterman, J. U.

AU - Bodey, G. P.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - In a prospective randomized trial, sc Corynebacterium parvum (C. parvum) immunotherapy did not significantly affect the response and survival of 49 non-oat cell lung cancer patients receiving isophosphamide and adriamycin chemotherapy. Remissions (tumor regression > 50%) were seen in five of 23 patients receiving an intensive C. parvum schedule and in three of 26 patients receiving a nonintensive C. parvum schedule (22% versus 12%). Median survival was 20 weeks for patients given intensive C. parvum and 23 weeks for patients given nonintensive C. parvum. This study did demonstrate the importance of pretherapy immunocompetence, performance status, and weight loss as predictors for survival. Weight loss was the most significant prognostic factor. Performance status was closely associated with weight loss but skin reactivity to dermatophytin predicted independently and was the second most important prognostic characteristic.

AB - In a prospective randomized trial, sc Corynebacterium parvum (C. parvum) immunotherapy did not significantly affect the response and survival of 49 non-oat cell lung cancer patients receiving isophosphamide and adriamycin chemotherapy. Remissions (tumor regression > 50%) were seen in five of 23 patients receiving an intensive C. parvum schedule and in three of 26 patients receiving a nonintensive C. parvum schedule (22% versus 12%). Median survival was 20 weeks for patients given intensive C. parvum and 23 weeks for patients given nonintensive C. parvum. This study did demonstrate the importance of pretherapy immunocompetence, performance status, and weight loss as predictors for survival. Weight loss was the most significant prognostic factor. Performance status was closely associated with weight loss but skin reactivity to dermatophytin predicted independently and was the second most important prognostic characteristic.

UR - http://www.scopus.com/inward/record.url?scp=0018099596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018099596&partnerID=8YFLogxK

M3 - Article

C2 - 356968

AN - SCOPUS:0018099596

VL - 62

SP - 1059

EP - 1063

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7

ER -